On November 12, Iovance Biotherapeutics, Inc. fell 5.25% in Regular Trading, trading at $7.68 per share, with turnover of $15.37 million.
The move followed a market reassessment after the company’s recent third-quarter results beat expectations on both earnings and revenue, but full-year product revenue guidance remained unchanged at $410 million to $420 million rather than being raised again.
For the quarter ended September 30, Iovance Biotherapeutics, Inc. reported a loss of $0.05 per share, better than consensus expectations of a $0.08 to $0.09 loss, while revenue rose to $121.5 million from $67.5 million a year earlier and topped expectations of about $116 million. Despite continued commercialization progress and narrower losses, the maintained guidance appears to have limited incremental upside after the sharp guidance increase disclosed in late September.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments